WallStreetZenWallStreetZen

NASDAQ: IRWD
Ironwood Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IRWD

Based on 3 analysts offering 12 month price targets for Ironwood Pharmaceuticals Inc

Min Forecast
$5.00+35.87%
Avg Forecast
$7.67+108.34%
Max Forecast
$10.00+171.74%

Should I buy or sell IRWD stock?

Based on 3 analysts offering ratings for Ironwood Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their IRWD stock forecasts and price targets.

IRWD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-26Find Out Why
lockedlocked$00.00+00.00%2026-01-05Find Out Why
lockedlocked$00.00+00.00%2026-01-05Find Out Why

1 of 1

Forecast return on equity

Is IRWD forecast to generate an efficient return?

Company
-38.28%
Industry
47.42%
Market
170.14%
IRWD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IRWD forecast to generate an efficient return on assets?

Company
19.13%
Industry
17.82%
IRWD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IRWD earnings per share forecast

What is IRWD's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$1.38+115.16%
Avg 2 year Forecast
$1.49+132.16%
Avg 3 year Forecast
$1.59+148.09%
IRWD's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

IRWD revenue forecast

What is IRWD's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$467.8M+29.39%
Avg 2 year Forecast
$488.3M+35.07%
Avg 3 year Forecast
$499.8M+38.26%
IRWD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IRWD earnings growth forecast

How is IRWD forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
35.41%
Industry
12.43%
Market
34.17%
IRWD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
IRWD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
IRWD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

IRWD revenue growth forecast

How is IRWD forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
11.53%
Industry
8.52%
Market
14.12%
IRWD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IRWD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IRWD vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
IRWD$3.68$7.67+108.34%Buy
TLRY$5.46$8.50+55.68%Strong Buy
AQST$4.13N/AN/A
KMDA$7.86$13.00+65.39%Buy
EOLS$6.72$15.50+130.65%Strong Buy
View Top Pharmaceutical Stocks

Ironwood Pharmaceuticals Stock Forecast FAQ

Is Ironwood Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: IRWD) stock is to Buy IRWD stock.

Out of 3 analysts, 0 (0%) are recommending IRWD as a Strong Buy, 2 (66.67%) are recommending IRWD as a Buy, 1 (33.33%) are recommending IRWD as a Hold, 0 (0%) are recommending IRWD as a Sell, and 0 (0%) are recommending IRWD as a Strong Sell.

If you're new to stock investing, here's how to buy Ironwood Pharmaceuticals stock.

What is IRWD's earnings growth forecast for 2026-2028?

(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual earnings growth rate of 35.41% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 12.43%, and it is also forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Ironwood Pharmaceuticals's earnings in 2026 is $102,176,000.On average, 6 Wall Street analysts forecast IRWD's earnings for 2026 to be $226,672,660, with the lowest IRWD earnings forecast at $185,519,309, and the highest IRWD earnings forecast at $300,748,693. On average, 6 Wall Street analysts forecast IRWD's earnings for 2027 to be $244,582,599, with the lowest IRWD earnings forecast at $209,717,479, and the highest IRWD earnings forecast at $300,748,693.

In 2028, IRWD is forecast to generate $261,373,166 in earnings, with the lowest earnings forecast at $222,623,170 and the highest earnings forecast at $307,662,456.

What is IRWD's revenue growth forecast for 2026-2028?

(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 11.53% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.

Ironwood Pharmaceuticals's revenue in 2026 is $361,514,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $77,001,212,925, with the lowest IRWD revenue forecast at $72,912,215,920, and the highest IRWD revenue forecast at $80,148,621,247. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $80,380,726,150, with the lowest IRWD revenue forecast at $75,336,971,390, and the highest IRWD revenue forecast at $84,953,686,568.

In 2028, IRWD is forecast to generate $82,278,718,721 in revenue, with the lowest revenue forecast at $76,304,898,217 and the highest revenue forecast at $89,205,650,845.

What is IRWD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IRWD) forecast ROA is 19.13%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.82%.

What is IRWD's Price Target?

According to 3 Wall Street analysts that have issued a 1 year IRWD price target, the average IRWD price target is $7.67, with the highest IRWD stock price forecast at $10.00 and the lowest IRWD stock price forecast at $5.00.

On average, Wall Street analysts predict that Ironwood Pharmaceuticals's share price could reach $7.67 by Feb 26, 2027. The average Ironwood Pharmaceuticals stock price prediction forecasts a potential upside of 108.34% from the current IRWD share price of $3.68.

What is IRWD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IRWD) Ironwood Pharmaceuticals's current Earnings Per Share (EPS) is $0.64. On average, analysts forecast that IRWD's EPS will be $1.38 for 2026, with the lowest EPS forecast at $1.13, and the highest EPS forecast at $1.83. On average, analysts forecast that IRWD's EPS will be $1.49 for 2027, with the lowest EPS forecast at $1.27, and the highest EPS forecast at $1.83. In 2028, IRWD's EPS is forecast to hit $1.59 (min: $1.35, max: $1.87).

What is IRWD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IRWD) forecast ROE is -38.28%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.